{"Clinical Trial ID": "NCT00605267", "Intervention": ["INTERVENTION 1:", "Anastrozole 1 mg", "Anastrozole (investigative product) 1 mg tablet administered orally once daily and goserelin acetate 3.6 mg/ month deposit injection", "INTERVENTION 2:", "Tamoxifene 20 mg", "Tamoxifen (comparator) 20 mg tablet administered orally once daily and gos\u00e9r\u00e9line acetate 3.6 mg/ month deposit injection"], "Eligibility": ["Incorporation criteria:", "Premenopausal women, positive estrogen receptors, aged 20 years and over, with operational and measurable breast cancer who have given their informed consent in writing", "- Exclusion criteria:", "Medical history of chemotherapy or endocrine treatment for breast cancer, or with a history of radiation therapy."], "Results": ["Performance measures:", "Best overall response rate (BORR) (Calliper)", "The RROB was defined as the percentage of patients with a confirmed CR or PR in the TTI population in the 24 weeks prior to treatment (based on calliper measurement data).", "By RECIST criteria (V1.0) and assessed by Calliper: Complete response (CR), elimination of all target lesions; Partial response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall response (RO) = CR + PR.", "Duration: 24 weeks", "Results 1:", "Title of arm/group: Anastrozole 1 mg", "Description of the arm/group: Anastrozole (investigative product) 1 mg tablet administered orally once daily and gos\u00e9r\u00e9line acetate 3.6 mg/ month deposit injection", "Total number of participants analysed: 98", "Type of measurement: Number", "Unit of measure: Percentage of participants 70.4", "Results 2:", "Title of arm/group: Tamoxifene 20 mg", "Description of the arm/group: Tamoxifene (comparator) 20 mg tablet administered orally once daily and gos\u00e9r\u00e9line acetate 3.6 mg/ month deposit injection", "Total number of participants analysed: 99", "Type of measurement: Number", "Unit of measure: Percentage of participants 50.5"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/98 (1.02 %)", "Benign neoplasm 1/98 (1.02%)", "Adverse Events 2:", "Total: 0/98 (0.00 per cent)", "Benign neoplasm 0/98 (0.00 per cent)"]}